Influenza virus-like particles containing M2 induce broadly cross protective immunity.

Current influenza vaccines based on the hemagglutinin protein are strain specific and do not provide good protection against drifted viruses or emergence of new pandemic strains. An influenza vaccine that can confer cross-protection against antigenically different influenza A strains is highly desir...

Full description

Bibliographic Details
Main Authors: Jae-Min Song, Bao-Zhong Wang, Kyoung-Mi Park, Nico Van Rooijen, Fu-Shi Quan, Min-Chul Kim, Hyun-Tak Jin, Andrew Pekosz, Richard W Compans, Sang-Moo Kang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3022578?pdf=render
id doaj-cf44169acb7f4e6e9c6aba49475e8e30
record_format Article
spelling doaj-cf44169acb7f4e6e9c6aba49475e8e302020-11-25T02:33:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0161e1453810.1371/journal.pone.0014538Influenza virus-like particles containing M2 induce broadly cross protective immunity.Jae-Min SongBao-Zhong WangKyoung-Mi ParkNico Van RooijenFu-Shi QuanMin-Chul KimHyun-Tak JinAndrew PekoszRichard W CompansSang-Moo KangCurrent influenza vaccines based on the hemagglutinin protein are strain specific and do not provide good protection against drifted viruses or emergence of new pandemic strains. An influenza vaccine that can confer cross-protection against antigenically different influenza A strains is highly desirable for improving public health.To develop a cross protective vaccine, we generated influenza virus-like particles containing the highly conserved M2 protein in a membrane-anchored form (M2 VLPs), and investigated their immunogenicity and breadth of cross protection. Immunization of mice with M2 VLPs induced anti-M2 antibodies binding to virions of various strains, M2 specific T cell responses, and conferred long-lasting cross protection against heterologous and heterosubtypic influenza viruses. M2 immune sera were found to play an important role in providing cross protection against heterosubtypic virus and an antigenically distinct 2009 pandemic H1N1 virus, and depletion of dendritic and macrophage cells abolished this cross protection, providing new insight into cross-protective immune mechanisms.These results suggest that presenting M2 on VLPs in a membrane-anchored form is a promising approach for developing broadly cross protective influenza vaccines.http://europepmc.org/articles/PMC3022578?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jae-Min Song
Bao-Zhong Wang
Kyoung-Mi Park
Nico Van Rooijen
Fu-Shi Quan
Min-Chul Kim
Hyun-Tak Jin
Andrew Pekosz
Richard W Compans
Sang-Moo Kang
spellingShingle Jae-Min Song
Bao-Zhong Wang
Kyoung-Mi Park
Nico Van Rooijen
Fu-Shi Quan
Min-Chul Kim
Hyun-Tak Jin
Andrew Pekosz
Richard W Compans
Sang-Moo Kang
Influenza virus-like particles containing M2 induce broadly cross protective immunity.
PLoS ONE
author_facet Jae-Min Song
Bao-Zhong Wang
Kyoung-Mi Park
Nico Van Rooijen
Fu-Shi Quan
Min-Chul Kim
Hyun-Tak Jin
Andrew Pekosz
Richard W Compans
Sang-Moo Kang
author_sort Jae-Min Song
title Influenza virus-like particles containing M2 induce broadly cross protective immunity.
title_short Influenza virus-like particles containing M2 induce broadly cross protective immunity.
title_full Influenza virus-like particles containing M2 induce broadly cross protective immunity.
title_fullStr Influenza virus-like particles containing M2 induce broadly cross protective immunity.
title_full_unstemmed Influenza virus-like particles containing M2 induce broadly cross protective immunity.
title_sort influenza virus-like particles containing m2 induce broadly cross protective immunity.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Current influenza vaccines based on the hemagglutinin protein are strain specific and do not provide good protection against drifted viruses or emergence of new pandemic strains. An influenza vaccine that can confer cross-protection against antigenically different influenza A strains is highly desirable for improving public health.To develop a cross protective vaccine, we generated influenza virus-like particles containing the highly conserved M2 protein in a membrane-anchored form (M2 VLPs), and investigated their immunogenicity and breadth of cross protection. Immunization of mice with M2 VLPs induced anti-M2 antibodies binding to virions of various strains, M2 specific T cell responses, and conferred long-lasting cross protection against heterologous and heterosubtypic influenza viruses. M2 immune sera were found to play an important role in providing cross protection against heterosubtypic virus and an antigenically distinct 2009 pandemic H1N1 virus, and depletion of dendritic and macrophage cells abolished this cross protection, providing new insight into cross-protective immune mechanisms.These results suggest that presenting M2 on VLPs in a membrane-anchored form is a promising approach for developing broadly cross protective influenza vaccines.
url http://europepmc.org/articles/PMC3022578?pdf=render
work_keys_str_mv AT jaeminsong influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT baozhongwang influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT kyoungmipark influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT nicovanrooijen influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT fushiquan influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT minchulkim influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT hyuntakjin influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT andrewpekosz influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT richardwcompans influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
AT sangmookang influenzaviruslikeparticlescontainingm2inducebroadlycrossprotectiveimmunity
_version_ 1724811460864901120